MG Stock Recent News
MG LATEST HEADLINES
PRINCETON JUNCTION, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (MG: NYSE) has scheduled a conference call for Thursday, May 8, 2025, at 9:00 am Eastern Standard Time to present its results for the first quarter of 2025. A press release with the first quarter results will be issued after the close of market on Wednesday, May 7, 2025.
First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older. First and only FcRn blocker approved in anti-AChR and anti-MuSK antibody positive adults and pediatric gMG patients aged 12 and older.
PRINCETON JUNCTION, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), the leading global provider of integrated, technology-enabled asset protection solutions, today announced the launch of MISTRAS Data Solutions, a unified brand that consolidates the company's data-centric services, software solutions, and technology under one umbrella.
PRINCETON JUNCTION, N.J., April 14, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), the leading provider of integrated technology-enabled asset protection solutions, today announced the appointment of Cliff Schaffer as Senior Vice President of In-Lab Services. Reporting to Hani Hammad, Executive Vice President and Chief Operating Officer, Schaffer will lead MISTRAS' in-lab strategy and operations across North America, with a focus on scaling services for aerospace and defense and heavy manufacturing sectors.
PRINCETON JUNCTION, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- MISTRAS Group, Inc. (NYSE: MG), the leading “one source” multinational provider of integrated technology-enabled asset protection solutions, will ring the opening bell at the New York Stock Exchange today, celebrating growing interest in, and adoption of, its asset protection solutions in energy, manufacturing, and aerospace and defense.
Mistras (MG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.